{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T07:27:54Z","timestamp":1748935674613},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Data are limited on the selection and sequencing of second-line and third-line pediatric antiretroviral treatment (ART) in resource-limited settings. This study aimed to evaluate characteristics of African pediatric patients initiated on darunavir (DRV) and\/or etravirine (ETR) through a specific drug donation program.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This was a cross-sectional study of baseline immunologic, virologic and demographic characteristics of children and adolescents initiating DRV-based and\/or ETR-based ART. Descriptive statistics were used.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Study enrolled 48 patients (45.8% women; median age = 15 years [interquartile range 17.7\u201310.3]) at 9 clinical sites in Zambia, Swaziland, Kenya and Lesotho. The majority (87.5%; n = 42) had received \u22652 prior ART regimens; most (81.2%) had received lopinavir\/ritonavir-based ART before switch. All patients had detectable HIV RNA (median = 56,653 copies\/mL). Forty seven patients (98.9%) had HIV genotype results: 41 (87.2%) had \u22651 nucleos(t)ide reverse transcriptase inhibitor (NRTI)-resistance mutation (RM), predominantly M184V (76.6%; n = 36); 31 (65.9%) had \u22651 non-NRTI-RM, including 27 (57.4%) with \u22651 ETR-RM; 30 (63.8%) had \u22653 protease inhibitor RM, including 20 (42.6%) with \u22651 DRV-RM. For new ART regimens, DRV and raltegravir were most frequently prescribed (83.3%; n = 40 on DRV and raltegravir, each). Eighteen patients (37.5%) were initiated on the NRTI-sparing ART.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In our study, a significant proportion of treatment-experienced African children and adolescents had one or more DRV-RM and ETR-RM. For the new regimen, more than a third of pediatric patients failing second-line ART were prescribed NRTI-sparing regimens. Better understanding of the current approaches to pediatric ART sequencing in resource-limited settings is needed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000001843","type":"journal-article","created":{"date-parts":[[2017,11,15]],"date-time":"2017-11-15T20:47:59Z","timestamp":1510778879000},"page":"669-672","source":"Crossref","is-referenced-by-count":6,"title":["Characteristics of Treatment-experienced HIV-infected African Children and Adolescents Initiating Darunavir and\/or Etravirine-based Antiretroviral Treatment"],"prefix":"10.1097","volume":"37","author":[{"given":"Bethany","family":"Corrigan","sequence":"first","affiliation":[{"name":"Technical Assistance and Sustainability, EGPAF, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Mukui","sequence":"additional","affiliation":[{"name":"National AIDS & STI Control Program, Ministry of Health, Nairobi, Kenya"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lloyd","family":"Mulenga","sequence":"additional","affiliation":[{"name":"Adult Infectious Diseases Centre, University Teaching Hospital, Lusaka, Zambia"},{"name":"School of Medicine, University of Zambia, Lusaka, Zambia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhle","family":"Mthethwa","sequence":"additional","affiliation":[{"name":"Ministry of Health, Mbabane, Swaziland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mosilinyane","family":"Letsie","sequence":"additional","affiliation":[{"name":"Disease Control, Ministry of Health, Maseru, Lesotho"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Bruno","sequence":"additional","affiliation":[{"name":"Technical Assistance and Sustainability, EGPAF, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natella","family":"Rakhmanina","sequence":"additional","affiliation":[{"name":"Technical Assistance and Sustainability, EGPAF, Washington, DC"},{"name":"Division of Infectious Diseases, Children\u2019s National Health System, Washington, DC"},{"name":"Department of Pediatrics The George Washington University School of Medicine and Health Sciences, Washington, DC."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R4-20230912","article-title":"Accelerating Children\u2019s HIV\/AIDS Treatment (ACT).","year":"August 6, 2014","journal-title":"Press release"},{"key":"R5-20230912","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/infdis\/jiw219","article-title":"Protease inhibitor resistance in the first 3 years of second-line antiretroviral therapy for HIV-1 in Sub-Saharan Africa.","volume":"214","author":"Boender","year":"2016","journal-title":"J Infect Dis"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1758-2652-14-55","article-title":"It is time to consider third-line options in antiretroviral-experienced paediatric patients?","volume":"14","author":"Zyl","year":"2011","journal-title":"J Int AIDS Soc"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/INF.0b013e31822db54c","article-title":"Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon.","volume":"30","author":"Fokam","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"21140","DOI":"10.7448\/IAS.19.1.21140","article-title":"High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children.","volume":"19","author":"Boerma","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"R9-20230912","doi-asserted-by":"crossref","first-page":"20683","DOI":"10.7448\/IAS.19.1.20683","article-title":"High rates of virological failure and drug resistance in perinatally HIV-1-infected children and adolescents receiving lifelong antiretroviral therapy in routine clinics in Togo.","volume":"19","author":"Salou","year":"2016","journal-title":"J Int AIDS Soc"},{"issue":"suppl 2","key":"R10-20230912","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1093\/infdis\/jit115","article-title":"Development of antiretroviral resistance in children with HIV in low- and middle-income countries.","volume":"207","author":"Fitzgerald","year":"2013","journal-title":"J Infect Dis"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1097\/QAI.0000000000001285","article-title":"HIV drug resistance mutations in non-B subtypes after prolonged virological failure on NNRTI-based first-line regimens in Sub-Saharan Africa.","volume":"75","author":"Kityo","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"suppl 2","key":"R12-20230912","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/infdis\/jit109","article-title":"Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.","volume":"207","author":"De Luca","year":"2013","journal-title":"J Infect Dis"},{"issue":"suppl 2","key":"R13-20230912","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1093\/infdis\/jit112","article-title":"Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy\u2013implications for sustained efficacy of ART in resource-limited settings.","volume":"207","author":"Hill","year":"2013","journal-title":"J Infect Dis"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1097\/INF.0000000000001481","article-title":"Second- and third-line antiretroviral therapy for children and adolescents: a scoping review.","volume":"36","author":"Lazarus","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/jac\/dkw218","article-title":"Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.","volume":"71","author":"Boender","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R22-20230912","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1468-1293.2010.00828.x","article-title":"HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.","volume":"11","author":"Puthanakit","year":"2010","journal-title":"HIV Med"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1468-1293.2010.00907.x","article-title":"Etravirine-based highly active antiretroviral therapy in HIV-1-infected paediatric patients.","volume":"12","author":"Briz","year":"2011","journal-title":"HIV Med"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/hiv.12141","article-title":"Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.","volume":"15","author":"Tudor-Williams","year":"2014","journal-title":"HIV Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201807000-00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:10:15Z","timestamp":1694556615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201807000-00010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000001843","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}